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To determine what genetic changes are selected in the enhancer sequences of the feline leukemia virus (FeLV) long 
terminal repeat in cats that develop T cell tumors, we cloned proviral U3 sequences in cats that died with thymic lymphoma 
following infection with molecularly cloned FeLV. Analysis of the U3 enhancer egion revealed single base changes, including 
point mutations in the core and FLV-1 sequences. Additionally, in clones from two of four cat tumors, portions of the 
enhancer including Lvb and core were duplicated with respect o the single enhancer unit of the inoculating virus. In contrast, 
a PCR survey of necropsy DNA samples derived from five cats that did not develop tumors revealed that all retained the 
single enhancer unit of the infecting virus. These results demonstrate that viruses with duplicated enhancers can be 
generated and selected after only a single passage in cats, and furthermore, that such viruses may be particularly selected 
in tumors, © 1995 Academic Press, Inc. 
Feline leukemia virus (FeLV) is a nonacute type C on- 
cogenic retrovirus that can induce tumors after a long 
latency (for a review see 1). Such nonacutely trans- 
forming retroviruses may rely on several mechanisms to 
induce neoplasia (for a review see 2). For example, the 
U3 region of the proviral long terminal repeat (LTR) could 
alter the transcriptional regulation of an adjacent host 
protooncogene. Thus, it is likely that in vivo selection 
for LTR changes that increase viral expression might 
incidentally create a more leukemogenic virus (2). 
In recent studies where proviruses were isolated di- 
rectly from FeLV-positive tumors (3) or where PCR was 
used to survey tumor-associated FeLV LTRs (4), dupli- 
cated enhancer regions were detected with high fre- 
quency. On the basis of these results, it has been as- 
sumed that enhancer duplications arise de novo from 
a single enhancer during infection and influence tumor 
formation. However, in studies of virus from naturally 
infected cats, the sequence of the originally infecting 
virus is unknown. Because viruses with duplicated en- 
hancers may already have been present in the inocula, 
it is possible that such viruses are selected for replication 
during transmission and/or early infection and are not 
specifically associated with leukemogenesis. 
To help clarify this matter, we used PCR to compare 
the U3 regions of a variety of necropsy samples taken 
from cats that died with or without tumors after infection 
with molecularly cloned FeLVs containing a single en- 
hancer. Table 1 describes the inocula and pathogenic 
outcome in cats from which the various DNA samples 
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were derived. The oligonucleotide primers FeLV-U3-1 
(5'GAAT-FCAAAAT-R-AGOCAGCTACTGCAG; 61 E LTR nu- 
cleotides 18 through 39) and FeLV-U3-2B (5'GCGGAAT- 
TCGAAGGTCGAACTCTGGTCAACT; 61E LTB nucleo- 
tides 231 through 252) were used to amplify U3 se- 
quences which, in the case of FeLV-61E (5), would yield 
a 235-bp single enhancer product. Italicized bases in the 
oligonucleotide sequences are restriction endonuclease 
digestion sites that do not correspond to FeLV se- 
quences. PCR was carried out with 1 unit of AmpliTaq 
polymerase (Perkin-Elmer-Cetus)in a buffer containing 
2.5 mM MgCI2, 0.2 mM of each of four dNTPs, 250 ng of 
each oligonucleotide primer, and 100 ng of total genomic 
DNA template. Thermal cycling conditions consisted of 
a 4-min initial denaturation at 94 °, followed by 35 cycles 
of a 1-min denaturation at 94 °, a 1-min annealing at 50 ° , 
and a 2-min extension at 72 °. 
Figure 1 shows an ethidium bromide-stained agarose 
gel of PCR product amplified with FeLV-U3-1 and FeLV- 
U3:2B from a variety of cat DNA samples. Specificity of 
products and lack of amplification in the control lanes 
were confirmed by Southern analysis with an exogenous 
LTR-specific probe (data not shown). The fragment of 
approximately 0.24 kb amplified from both a plasmid con- 
taining the 61E genome (p61E) and JOAHE4, an AH927 
feline fibrobtast cell line chronically infected with 61E, 
represents product from an LTR with a single enhancer. 
A fragment of this size was detected in all infected cat 
tissue DNAs. In addition, PCR product from at least two 
of four cats that died with tumors (cat 40681 tumor and 
bone marrow, cat 1669 tumor and mesenteric lymph 
node) displayed more than one FeLV-specific fragment. 
Multiple fragments were also seen consistently in cat 
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TABLE 1 
CATS INOCULATED WITH MOLECULARLY CLONED FeLV 
Oat Inoculant Outcome of infection Reference 
40681 61E Death= thymic tumor, 6 
424 days PI a 
40836 61E Death, thymic tumor, 6 
343 days PI 
1879 82K and 61E Death: thymic tumor, 24 
716 days PI 
1669 61B and 61E Death, thymic tumor, 24 
950 days PI 
1877 82K and 61E Death: degenerative, 24 
1431 days PI 
1673 61B and 61E Death, FAIDS, 294 days PI 24 
1671 61B and 61E Death~ FAIDS, 231 days PI 24 
1862 61-1 and 61E Death: FAIDS, 220 days PI 24 
1390 3281 Death= neurological disorder, 23 
28 months PI 
a PI, postinoculation. 
40836 tumor, but they were present at low abundance. 
In cat 1669 samples, the approximately 0.24-kb fragment 
was as prominent as several larger fragments, which 
ranged from 0.30 to 0.60 kb. Conversely, in cat 40681 
tumor product, the expected 0.24-kb fragment was not 
as prevalent as the single larger fragment of approxi- 
mately 0.28 kb. In contrast to the samples from cats 
with tumors, we did not detect duplicated enhancers in 
samples from each of five cats that died from diseases 
other than tumors (Table 1). This observation is in general 
agreement with the findings of Matsumoto and co-work- 
ers (4), who showed that only a low frequency (16%) of 
naturally infected cats lacking tumors contained provi- 
ruses with multiple enhancers. Thus, in cats infected with 
a molecular clone of FeLV, the evolution of duplicated 
enhancers from a single enhancer is more prevalent in 
cats that die with tumors than in those that die of other 
complications. 
In order to more closely inspect the enhancer region 
of proviruses in cats with tumors, we analyzed the U3 
sequences from the four cats that died with thymic 
lymphoma and, as a negative control, one cat (1877) that 
died of a degenerative disorder. The cloning of products 
spanning the 3' portion of the proviral genome from vari- 
ous cat tissue genomic DNAs was described previously 
(6). Briefly, to study both envelope gene (env) and LTR 
changes, we amplif ied a region of FeLV containing env 
and the U3 region of the LTR using the primers FeLV- 
pol-5 (5 'GCGTCTAGACTCTCGTGGAACTFAGTGT;  61E 
proviral nucleotide positions 6023 through 6041) and 
FeLV-U3-2B, as described above. We then cloned these 
fragments into the vector M13mp18 and determined the 
nucleotide sequences in the enhancer region using the 
dideoxy chain termination method (7). Analysis of the 
env gene sequences of these clones has been reported 
previously (6). 
Figure 2 shows an al ignment of the partial U3 se- 
quences of POR clones derived from these five cats with 
respect to the nucleotide sequence of the inoculated 
molecularly cloned viruses 61E, 82K, or 61B. Overall, a 
small number of point mutations were seen. Interestingly, 
the majority of clones from 1877 jejunum (Fig. 2A) as 
well as from bone marrow and tumor of cat 1879 (Figs. 
2B and 2C) shared the two nucleotide differences found 
in the coinoculant 82K relative to 61E (T-to-G at position 
109 and G-to-A at position 180). Given that no evidence 
of 82K proviruses was seen in Southern blot analyses of 
necropsy DNA samples from these two animals, and that 
only 61 E-like env sequences were found in these same 
PCR clones (6, 8), it is likely that proviruses in these cats 
represent recombinant genomes containing 61E envand 
82K LTR. Further, these nucleotide changes may confer 
some selective advantage to the virus given that they are 
the dominant genotype in clones from both cats inocu- 
lated with 61E and 82K. 
Certain clones contained additional point mutations. 
First, two of the tumor-derived clones (clones 79-I-F-36 
and 79TT-25) from cat 1879 contained nucleotide 
7 ,  ,~ , "t, . . . . . .  , 
676 - -  
497  - -  
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FIG. 1. PCR of U3 region of proviruses from cat necropsy samples. 
PCR using the primer pairs FeLV-U3-1 and FeLV-U3-2B was performed 
on 100 ng of the following genomic DNA samples= cat 40681 tumor 
(TU) and bone marrow (BM), cat 40836 TU and BM, cat 1879 TU and 
BM, cat t669 TU and mesenteric lymph node (MLN), cat 1877 jejunum 
(JE), cat 1673 MLN, cat 1671 MLN, cat 1862 MLN, cat 1390 MLN, an 
AH927 cell line chronically infected with 61E (JOAHE4), and an unin- 
fected feline T cell line (3201). Also amplified were 0.01 fg of a plasmid 
containing the complete 61E genome (p61E), which represents approxi- 
mately one copy of the provirus and is the iowest amount yielding 
detectable levels of product under these PCR conditions, and a water 
control (no DNA). Product was subjected to electrophoresis in 2.2% 
agarose and stained with ethidium bromide. Reactions were performed 
in triplicate and on multiple occasions, and the results were consistent 
for each cat. PCR product from a representative reaction is shown. 
Horizontal lines to the left of the photograph indicate the sizes in bp 
of the molecular weight standard, a digest of pUCl 8 with the restriction 
endcnuclease AspHI. The arrow to the left indicates the approximate 
location of the product expected from a 61E provirus bearing a single 
enhancer (235 bp). 
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GAC CTG TTCAAAACAC<~ATATCt~G~X~qU~AAGCAC CTGGGC C C 
AGATACAAGGAAGTTAGAGGCTAAAACAGGATATCTG~G~TTAAGCACCTGGGCC~CG~9c~PGAGGCCAAGAACAGTTAAACCCCGGATATAGCTGAAA~AGCAGAAGT~FFCAAGGCCGCTGCCAGCAGTCTCCAGGCTCCCC 
A GATACA%GGAA~AGAGGCTAAAACAGGATATCT~GGq~fAAGCACCTGGGCCCCGGC~GAGGC~AA~CAGTTAAACCCCGGATATAGCTGAAACAGCAGA%GTTTCAAGGC~C-~ ~CCAGCAGTCTCCAGGCTCCCC 
FIG. 2. Comparison of the nucleotide sequence of 61E in the U3 region of the 3'* LTR with those of clones derived from cat necropsy 
samples. Clones were generated from PCR product amplified with the primer pair FeLV-pol-5 and FeLV-U3-2B as described previously (6) 
using the following genomic DNA as a template= cat 1877 jejunum (A), cat 1879 bone marrow (B), cat 1879 tumor (C), cat 1669 tumor (D), 
cat 40681 tumor (E), cat 40836 tumor (F), and JQAHE4 cells (G). Sequences in the FeLV-U3 that are known to bind proteins and likely 
function as enhancer sequences (3) are indicated in the 61E sequence, :which is repeated at the top of each panel for clarity. Numbering 
is with respect to the first nucleotide of the FeLV 61E provirus (GenBank No. M18247). Nucleotide differences in each PCR clone are shown 
below the 61E sequence; dots indicate no change in nucleotide An asterisk indicates that the sequences shown below the panel are 
inserted at that position; a space in the parental sequence was added at the site of the insertion to allow correct alignment. At the top of 
the figure, the nucleotide sequences of the coinoculated molecular clones 82K and 61B are aligned underneath that of 61E for comparison. 
Brackets above the 61E sequence of D and E encompass the region duplicated in sequences aligned below. 
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changes in the protein-binding motif FLV-1, a putative 
negative regulatory element that binds a protein factor 
in fibroblast but not T cell tumor extracts (Fig. 2C) (3). 
Second, all six 40681 tumor-derived clones (Fig. 2E) con- 
tained the same A-to-C substitution at the second to 
last nucleotide of the core motif (FeLV nucleotide 131). 
Nothing is known about the nature and specificity of 
feline proteins that bind FeLV core or FLV-1 sequences. 
Two nucleotide changes in the Moloney MuLV core se- 
quence were sufficient to alter the disease specificity 
from lymphoma to erythroleukemia of viruses bearing 
these changes (9). In addition, substitution of the nonleu- 
kemogenic murine Akv virus core sequence into the LTR 
of the leukemogenic SL3-3 virus caused a decrease in 
transcription of a heterologous reporter gene in T- 
lymphoma cells (10). Thus, it is possible that minor alter- 
ations in the FeLV core sequence might affect transcrip- 
tional efficiency. Based on mutagenesis studies in the 
related SV40 core motif, where the second to last nuclee- 
tide is a G in the wild-type virus, the presence of a G-te- 
A mutation in conjunction with two other mutations in 
core abolished enhancer function in a reporter gene 
assay (11). Additionally, in each of the FeLV proviruses 
cloned from one of four naturally occurring thymic tumors 
analyzed by Matsumoto and co-workers (4), a G was 
found in the second to last core position. These data 
suggest that an A may not be favored at this position, 
and so the mutation of Ate C at FeLV position 131 might 
increase protein binding and, consequently, transcrip- 
tional efficiency. Finally, scattered point mutations were 
also observed, one in Lvb (clone 81qq--3, Fig. 2E) and 
others in regions where protein binding sites have not 
been identified. 
Env-LTR clones isolated from two animals, cats 1669 
and 40681, contained duplicated enhancers. In the case 
of cat 1669 thymic tumor-derived PCR clones (Fig. 2D), 
clone 69TT-1 contained an 83-bp direct repeat insertion 
encompassing the enhancer motifs Lvb, core, NF-1, and 
GRE. This clone likely corresponds to the approximately 
0.30-kb fragment detected by PCR of the U3 region (Fig. 
1); a ratio of one in six clones containing this insertion 
is consistent with the relative amounts of 0.30- to 0.24- 
kb fragment amplified in the PCR. Despite the fact that 
specific fragments larger than 0.30 kb were also present 
in that PCR product, we did not obtain clones containing 
larger insertions; it is possible that we selected against 
such clones when we isolated the 3' subgenomic frag- 
ment of the size expected for proviruses with a single 
enhancer (2.2 kb). All six 40681 clones (Fig. 2E) contained 
a distinct, smaller direct repeat insertion of 43 bp that 
also included the core and Lvb motifs, preceded by 9 
nucleotides of unknown origin. These clones probably 
correspond to the approximately 0.28-kb fragment de- 
tected asthe most abundant product in PCR amplification 
of the U3 region (Fig. 1). Although additional fragments 
were faintly detected by PCR of the U3 region using cat 
40836 tumor DNA (Fig. 1), none of the four clones we 
isolated from this DNA contained insertions (Fig. 2F), 
probably because such proviruses are relatively rare. 
Because both cats 40681 and 40836 were originally 
inoculated with cell-free supernatant from JOAHE4 cells 
(6), we wanted to explore the formal possibility that vi- 
ruses bearing duplicated enhancers arose during the 
limited culturing prior to inoculation. Six PCRs of the U3 
region revealed no evidence of a proviral species with 
additional sequences in JOAHE4 genomic DNA (Fig. 1 
shows a representative result). By using mixtures of FeLV 
plasmids containing single or double enhancers in a 
competitive PCR of the U3 region, we determined that 
detection of the double enhancer species was possible 
when it represented 2% or more of the LTR species (data 
not shown). We also wanted to confirm that the proviral 
U3 sequence in JOAHE4 resembled that of 61E. Three 
clones isolated from JOAHE4 genomic DNA (Fig. 2G) 
contained nucleotide sequences identical to 61E in the 
U3 region, consistent with the detection of only 0.24-kb 
product in PCR of the U3 region (Fig. 1). The presence 
of a single enhancer U3 configuration in these previral 
clones strengthens the evidence that duplicated en- 
hancers arose de novo in cat 40681 and possibly cat 
40836 during a single in vivo passage. 
A recent comparative analysis of U3 sequences of a 
number of mammalian type C retroviruses demonstrated 
that the Lvb and core motifs are among the most highly 
conserved and most frequently duplicated of the en- 
hancer sequences (12). In the MuLV system, viruses with 
two copies of the enhancer sequence were associated 
with shorter time to disease compared to viruses with 
one copy (13-16). Recently, MuLVs with two enhancer 
elements were shown to evolve directly from a molecu- 
larly cloned virus with a single element in AKR mice with 
thymic lymphoma (17). Also, spontaneous leukemogene- 
sis in AKR mice was shown to be associated with the 
evolution of an MCF virus containing a duplication of 
the enhancer region derived from an endogenous parent 
sequence (18). In the FeLV system, duplicated enhancers 
have been shown to cause a modest increase in the 
transcription of a downstream heterologous reporter 
gene (19). Thus, the evolution of FeLVs with multiple 
enhancers could increase the likelihood of upregulating 
a host protooncogene during insertional mutagenesis. 
Indeed, the current study complements previous studies 
(20, 21) of tumors from three members of this cohort (cats 
1879, 1669, and 40681), which demonstrated enhanced 
expression of flvi-2, a common locus for FeLV integration 
in thymic lymphoma (22). Therefore, viral variants bearing 
alterations in U3 enhancer sequences might have con- 
tributed to cellular transformation by increasing expres- 
sion of flvi-2, although we do not known which provirus 
lies proximal to the locus. This process may have been 
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facilitated by superinfection allowed by viruses con- 
taining defective envelope genes, which were previously 
shown to be prominent in the tumor tissue of the cats in 
this cohort (6). 
The U3 sequences described in this report are avail- 
able from GenBank under Accession Nos. L36321 to 
L36324, U03166 to U03169, U03176 to U03177, @03181 
to U03183, U03185, U03199 to U03203, U03210 to 
U03215, and U03228 to U03233. 
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